News Search Results
Aug 31, 2026, 07:30 ET Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
VELCADE® (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; and (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma. XPOVIO® (also known as NEXPOVIO® in certain countries) has received regulatory
More news about: Karyopharm Therapeutics Inc.
Aug 31, 2026, 07:00 ET BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and by Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop
More news about: BioLineRx Ltd.
Aug 28, 2026, 08:00 ET BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and by Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop
More news about: BioLineRx Ltd.
Aug 26, 2026, 07:00 ET HaemaLogiX Announces Major Milestone with First Patient Successfully Dosed with KMCAR™ T-Cell
pneumonia. Multiple myeloma is the second-most common haematological cancer worldwide. In 2022, the World Health Organisation (WHO)/Global Cancer Observatory (Globocan) estimated that approximately 543,000 people live with multiple myeloma globally, and approximately 188,000 new cases of multiple myeloma diagnosed
More news about: HaemaLogiX Ltd
Aug 25, 2026, 08:44 ET Fosun Pharma Announces 2026 Interim Results
has been accepted and granted priority review by the NMPA.- The NDA for Velinotamig (GR1803), a BCMA × CD3 bispecific antibody for multiple myeloma, has been accepted.Lead pipeline candidates HLX43 and HLX22 are progressing in international multi-center trials across China, the US, Europe,
More news about: Fosun Pharma
Aug 25, 2026, 07:00 ET BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop
More news about: BioLineRx Ltd.
Aug 24, 2026, 20:30 ET Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).To
More news about: Antengene Corporation Limited
Aug 23, 2026, 21:00 ET Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).To
More news about: Antengene Corporation Limited
Aug 21, 2026, 10:00 ET Greenberg Traurig's Brad Kaufman Named Finalist for American Lawyer Industry Awards Best Mentor
he also has focused on mentoring younger lawyers and advocating for mentorship opportunities across the firm. After being diagnosed with multiple myeloma in 2023, Kaufman returned to work wanting to do even more. Over the past year, he has traveled to Greenberg Traurig offices around the world to share
More news about: Greenberg Traurig, LLP
Aug 19, 2026, 08:32 ET Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix's role as a specialized global leader in registrational oncology trials.
More news about: Hematogenix
Aug 18, 2026, 21:00 ET Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).To
More news about: Antengene Corporation Limited
Aug 18, 2026, 20:15 ET CARsgen Therapeutics Announces 2026 Interim Results
approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have progressed after at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent) in 2024. In December
More news about: CARsgen Therapeutics
Aug 13, 2026, 07:30 ET Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
results, the Company has prioritized future investment toward its myelofibrosis and multiple myeloma programs while continuing long-term follow-up of patients enrolled in XPORT-EC-042.Multiple MyelomaPatients enrolled in the Phase 3 XPORT-MM-031 trial (EMN29;
More news about: Karyopharm Therapeutics Inc.
Aug 10, 2026, 07:30 ET Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is
More news about: Karyopharm Therapeutics Inc.
Aug 04, 2026, 09:48 ET Ochsner ranked No.1 in Louisiana by U.S. News & World Report
attackHeart bypass surgeryHeart failureHip fractureHip replacementKnee replacementLeukemia, lymphoma and myelomaLung cancer surgeryPacemaker implantationPneumoniaProstate cancer surgeryStrokeTranscatheter aortic
More news about: Ochsner Health
Aug 04, 2026, 06:00 ET Grady Recognized as U.S. News & World Report High Performing Hospital
earned top marks for care in Chronic Obstructive Pulmonary Disease (COPD), Heart Arrhythmia, Heart Failure, Kidney Failure, Leukemia, Lymphoma, and Myeloma, and Stroke. This is the highest distinction a hospital can earn as part of U.S. News' Best Hospitals Procedures & Conditions ratings.
More news about: Grady Health System
Aug 04, 2026, 05:00 ET MemorialCare Hospitals Recognized by U.S. News & World Report's 2026-2027 Best Hospitals in 38 High-Performing Rankings, One National in OB GYN
& Myeloma, Pacemaker Implantation and Pneumonia.Saddleback Medical Center earned High Performing ratings in 10 adult procedures and conditions: Abdominal Aortic Aneurysm Repair, Back Surgery (Spinal Fusion), Heart Arrhythmia, Heart Attack, Heart Failure, Leukemia, Lymphoma & Myeloma, Lung
More news about: MemorialCare
Aug 03, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1
More news about: Karyopharm Therapeutics Inc.
Jul 31, 2026, 07:47 ET AbbVie Reports Second-Quarter 2026 Financial Results
blood cancers, including oral presentations in prostate cancer, small cell lung cancer (SCLC), platinum-resistant ovarian cancer (PROC) and multiple myeloma (MM).At the European Hematology Association (EHA) 2026 Congress, AbbVie presented data that reinforced its leadership
More news about: AbbVie
Jul 30, 2026, 16:06 ET Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
VELCADE® (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; and (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma. XPOVIO® (also known as NEXPOVIO® in certain countries) has received regulatory
More news about: Karyopharm Therapeutics Inc.
Jul 30, 2026, 16:05 ET Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
VELCADE® (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; and (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma. XPOVIO® (also known as NEXPOVIO® in certain countries) has received regulatory
More news about: Karyopharm Therapeutics Inc.
Jul 24, 2026, 13:14 ET Society of Hematologic Oncology launches 2nd podcast focused on educational content in hematologic malignancies
Each episode offers in-depth conversations on emerging therapies and practice-changing developments in leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms—providing clinicians with timely, real-world perspectives from
More news about: Society of Hematologic Oncology
Jul 23, 2026, 08:30 ET TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
response and overall survival (OS).About Multiple Myeloma Multiple myeloma is a complex blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.2 In multiple myeloma, these plasma cells proliferate and spread rapidly and
More news about: Johnson & Johnson
Jul 23, 2026, 08:05 ET Accord BioPharma Announces Commercial Availability of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
obligations related to such warning.1 JUBEREQ is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is
More news about: Accord BioPharma
Jul 20, 2026, 11:00 ET ARUP Launches First Clinical Spectral Flow Cytometry Assay for MRD Assessment in Multiple Myeloma
CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry. The new assay will characterize small neoplastic populations with greater confidence and sensitivity than conventional flow cytometry, providing deep minimal residual disease (MRD) profiling for patients who have multiple myeloma.
More news about: ARUP Laboratories